Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
Nadine Gehrke, Jörn M. Schattenberg
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1929-1947.e6
Closed Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 464
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 361
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 287
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Cheng Peng, Alastair G. Stewart, Owen L. Woodman, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 180
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Erik J. Tillman, Timothy P. Rolph
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 161
IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis
Debanjali Dasgupta, Yasuhiko Nakao, Amy S. Mauer, et al.
Gastroenterology (2020) Vol. 159, Iss. 4, pp. 1487-1503.e17
Open Access | Times Cited: 141
Defining comprehensive models of care for NAFLD
Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 10, pp. 717-729
Closed Access | Times Cited: 104
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
James A. Thomas, Bradley J. Kendall, Hashem B. El‐Serag, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 2, pp. 159-169
Closed Access | Times Cited: 40
Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression
Christian Labenz, Yvonne Huber, Maurice Stephan Michel, et al.
Hepatology Communications (2020) Vol. 4, Iss. 9, pp. 1293-1301
Open Access | Times Cited: 91
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
Jiajia Chen, Xiaoyi Deng, Yongjian Liu, et al.
International Journal of Biological Sciences (2020) Vol. 16, Iss. 13, pp. 2367-2378
Open Access | Times Cited: 81
Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease
Jieling Xiao, Lincoln Kai En Lim, Cheng Han Ng, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 68
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Matthias Pinter, David J. Pinato, Pierluigi Ramadori, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 513-520
Open Access | Times Cited: 58
Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease
Ronan Thibaut, Matthew Gage, Inés Pineda‐Torra, et al.
FEBS Journal (2021) Vol. 289, Iss. 11, pp. 3024-3057
Open Access | Times Cited: 55
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S43-S57
Open Access | Times Cited: 55
The pathophysiology of MASLD: an immunometabolic perspective
Julian Schwärzler, Felix Grabherr, Christoph Grander, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 4, pp. 375-386
Closed Access | Times Cited: 25
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
Christoph Roderburg, Sarah Krieg, Andreas Krieg, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 21
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
David Medina‐Julio, Mariana M. Ramírez-Mejía, Jacqueline Córdova‐Gallardo, et al.
Medical Science Monitor (2024) Vol. 30
Open Access | Times Cited: 12
Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?
Elena Domingo, Patrice Marqués, Vera Francisco, et al.
Pharmacological Research (2024) Vol. 200, pp. 107058-107058
Open Access | Times Cited: 11
Role of sex and high-fat diet in metabolic and hypothalamic disturbances in the 3xTg-AD mouse model of Alzheimer’s disease
Lisa S. Robison, Olivia J. Gannon, Melissa A. Thomas, et al.
Journal of Neuroinflammation (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 63
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success
Joost P.H. Drenth, Jörn M. Schattenberg
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 12, pp. 1365-1375
Open Access | Times Cited: 62
Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
Manu V. Chakravarthy, Mohammad Shadab Siddiqui, Mikael Forsgren, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 62
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation
Xiaoyan Cai, Sulin Zheng, Ying Liu, et al.
Liver International (2020) Vol. 40, Iss. 7, pp. 1594-1600
Closed Access | Times Cited: 61
Non‐alcoholic fatty liver disease increases the risk of incident chronic kidney disease
Leonard Kaps, Christian Labenz, Peter R. Galle, et al.
United European Gastroenterology Journal (2020) Vol. 8, Iss. 8, pp. 942-948
Open Access | Times Cited: 52
Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease
María Luz Martínez‐Chantar, Teresa C. Delgado, Naiara Beraza
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 51
Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways
Yanyan Wang, Yunling Tai, Derrick Zhao, et al.
Cells (2021) Vol. 10, Iss. 2, pp. 210-210
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top